Roche puts Genentech in context
"We consolidate not only Genentech sales but also all the Genentech expenses in our P&L," Roche CEO Franz Humer tells Aug. 15 conference call. "We are really in that sense looking at Genentech sales as products which in the U.S. we simply sell through a different sales organization, but it is one Roche company"
You may also be interested in...
Roche will have "opt-in" rights on Chugai's Phase II rheumatoid arthritis agent in the U.S. as part of the merger agreement between the two firms
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011